Valuation Exelixis, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 23:00:00 26/06/2026 +03			Pre-market 15:30:49
54.77 ^USD	+2.89%		55.38	+1.10%

12:51pm	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Defensive Index	CI
06-22	Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	5,784	5,174	7,460	9,510	11,799	13,767	-	-
Change	-	-10.54%	44.19%	27.47%	24.07%	16.68%	-	-
Enterprise Value (EV) ¹	4,317	3,865	6,465	8,399	10,740	12,997	12,036	10,778
Change	-	-10.45%	67.25%	29.91%	27.88%	21.01%	-7.39%	-10.45%
P/E	25.4x	28.6x	36.9x	18.9x	15.8x	17.2x	14.8x	12.1x
PBR	2.64x	2.09x	3.21x	4.18x	5.32x	4.91x	3.63x	2.72x
PEG	-	-1.3x	2.3x	0x	0.3x	1.2x	0.9x	0.5x
Capitalization / Revenue	4.03x	3.21x	4.08x	4.39x	5.09x	5.3x	4.71x	4.26x
EV / Revenue	3.01x	2.4x	3.53x	3.87x	4.63x	5x	4.12x	3.33x
EV / EBITDA	14.4x	17.4x	32.9x	13.3x	11.9x	11.7x	9.61x	6.76x
EV / EBIT	15.1x	19.2x	37.8x	13.9x	12.3x	12.8x	10.1x	7.71x
EV / FCF	12.8x	17.2x	22.1x	12.5x	12.3x	16.4x	12.9x	7.43x
FCF Yield	7.8%	5.8%	4.53%	8%	8.15%	6.08%	7.75%	13.5%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	0.72	0.56	0.65	1.76	2.78	3.176	3.691	4.513
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	1,435	1,611	1,830	2,169	2,320	2,599	2,922	3,235
EBITDA ¹	300.3	222.4	196.6	633.4	901.2	1,107	1,253	1,593
EBIT ¹	286.7	201.5	170.9	604.6	872.2	1,016	1,192	1,398
Net income ¹	231.1	182.3	207.8	521.3	782.6	818.2	934.3	1,109
Net Debt ¹	-1,467	-1,308	-995.3	-1,111	-1,059	-770.1	-1,731	-2,988
Reference price ²	18.28	16.04	23.99	33.30	43.83	54.77	54.77	54.77
Nbr of stocks (in thousands)	316,397	322,561	310,974	285,579	269,203	251,355	-	-
Announcement Date	2/17/22 A	2/7/23 A	2/6/24 A	2/11/25 A	2/10/26 A	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
EXELIXIS, INC.	17.25x	5x	11.74x	-.--%	13.77B
ARGENX SE	34.2x	8.53x	26.72x	0.05%	55.63B
WUXI APPTEC CO., LTD.	19.78x	6x	13.04x	1.52%	52.25B
BIONTECH SE	-18.16x	4.33x	-7.56x	-.--%	23.07B
INSMED INCORPORATED	-39.15x	12.94x	-37.74x	-.--%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	21.62x	4.23x	10.97x	-.--%	17.32B
GENMAB A/S	22.36x	4.48x	14.84x	-.--%	15.94B
PHARMAESSENTIA CORPORATION	44.46x	16.86x	51x	-.--%	13.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-436.4x	29.85x	-3327.81x	-.--%	12.43B
MADRIGAL PHARMACEUTICALS, INC.	-74.63x	7.55x	-67.7x	-.--%	11.82B
Average	-40.87x	9.98x	-331.25x	0.16%	23.81B
Weighted average by Cap.	-13.02x	8.73x	-166.90x	0.35%